Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/44936
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorMACHADO, M. C.-
dc.contributor.authorCESCATO, V. A. S.-
dc.contributor.authorFRAGOSO, M. C. B. V.-
dc.contributor.authorBRONSTEIN, M. D.-
dc.date.accessioned2022-03-16T18:35:32Z-
dc.date.available2022-03-16T18:35:32Z-
dc.date.issued2021-
dc.identifier.citationAACE CLINICAL CASE REPORTS, v.7, n.4, p.277-281, 2021-
dc.identifier.issn2376-0605-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/44936-
dc.description.abstractObjective: The cyclicity (CIC) of cortisol spontaneously occurs in a minority of patients with Cushing syndrome (CS). When it arises, diagnostic and therapeutic approaches become more challenging. This study aimed to report a patient with Cushing disease (CD) who achieved normalization of cortisol and CIC pattern with pasireotide long-acting release (pasi/LAR). Methods: A 43-year-old female patient related an 8-month history of CS. An 8-mm pituitary nodule depicted by magnetic resonance imaging, serum cortisol suppression of >50% after 8 mg of dexamethasone therapy, and the absence of other lesions were compatible with a CD diagnosis. The patient presented with a CIC pattern with 1 episode before and 17 episodes after an unsuccessful pituitary surgery. Results: Medical treatment with cabergoline alone up to 3.5 mg/wk and a combined treatment with ketoconazole 400 mg/d did not improve CIC CS. Pasi/LAR was initiated at a dose of 20 mg/mo. A few days after the first dose, the patient experienced symptoms suggestive of adrenal insufficiency. The medication and dose were maintained for 24 months. During this period, there was a normalization of UFC levels and progressive clinical improvement. Additionally, new episodes of CIC were not observed. Conclusion: A CD patient with a challenging issue of CIC was reported. The condition was not controlled after pituitary surgery and by the combined treatment with cabergoline and ketoconazole, although hypercortisolism was abated by the continuous use of pasi/LAR. To our knowledge, this is the first report as regards the use of this medication to control CIC in a patient with CD. © 2021 AACEeng
dc.language.isoeng-
dc.publisherELSEVIER B.V.eng
dc.relation.ispartofAace Clinical Case Reports-
dc.rightsrestrictedAccesseng
dc.subjectCushing diseaseeng
dc.subjectCushing syndromeeng
dc.subjectcyclicityeng
dc.subjectpasireotideeng
dc.subjectpasireotide LAReng
dc.titleResolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Diseaseeng
dc.typearticleeng
dc.rights.holderCopyright ELSEVIER B.V.eng
dc.identifier.doi10.1016/j.aace.2021.02.007-
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.description.beginpage277-
hcfmusp.description.endpage281-
hcfmusp.description.issue4-
hcfmusp.description.volume7-
hcfmusp.origemSCOPUS-
hcfmusp.origem.id2-s2.0-85123917809-
hcfmusp.relation.referenceAlexandraki, K.I., Kaltsas, G.A., Isidori, A.M., The prevalence and characteristic features of cyclicity and variability in Cushing's disease (2009) Eur J Endocrinol, 160 (6), pp. 1011-1018eng
hcfmusp.relation.referenceNieman, L.K., Biller, B.M., Findling, J.W., Endocrine Society. Treatment of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline (2015) J Clin Endocrinol Metab, 100 (8), pp. 2807-2831eng
hcfmusp.relation.referenceBeckers, A., Stevenaert, A., Pirens, G., Flandroy, P., Sulon, J., Hennen, G., Cyclical Cushing's disease and its successful control under sodium valproate (1990) J Endocrinol Invest, 13 (11), pp. 923-929eng
hcfmusp.relation.referenceWatanobe, H., Aoki, R., Takebe, K., Nakazono, M., Kudo, M., In vivo and in vitro studies in a patient with cyclical Cushing's disease showing some responsiveness to bromocriptine (1991) Horm Res, 36 (5-6), pp. 227-234eng
hcfmusp.relation.referenceColao, A., Petersenn, S., Newell-Price, J., Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease (2012) N Engl J Med, 366 (10), pp. 914-924eng
hcfmusp.relation.referenceLacroix, A., Gu, F., Gallardo, W., Pasireotide G2304 Study Group. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial (2018) Lancet Diabetes Endocrinol, 6 (1), pp. 17-26eng
hcfmusp.relation.referencede Bruin, C., Pereira, A.M., Feelders, R.A., Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas (2009) J Clin Endocrinol Metab, 94 (4), pp. 1118-1124eng
hcfmusp.relation.referenceMeinardi, J.R., Wolffenbuttel, B.H., Dullaart, R.P., Cyclic Cushing's syndrome: a clinical challenge (2007) Eur J Endocrinol, 157 (3), pp. 245-254eng
hcfmusp.relation.referenceNieman, L.K., Biller, B.M., Findling, J.W., The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline (2008) J Clin Endocrinol Metab, 93 (5), pp. 1526-1540eng
hcfmusp.relation.referenceJahandideh, D., Swearingen, B., Nachtigall, L.B., Klibanski, A., Biller, B.M.K., Tritos, N.A., Characterization of cyclic Cushing's disease using late night salivary cortisol testing (2018) Clin Endocrinol (Oxf), 89 (3), pp. 336-345eng
hcfmusp.relation.referenceJang, Y.S., Lee, I.S., Lee, J.M., Choi, S.A., Kim, G.J., Kim, H.S., Diagnosis of cyclic Cushing syndrome using the morning urine free cortisol to creatinine ratio (2016) Korean J Intern Med, 31 (1), pp. 184-187eng
hcfmusp.relation.referenceLiberman, B., Wajchenberg, B.L., Tambascia, M.A., Mesquita, C.H., Periodic remission in Cushing's disease with paradoxical dexamethasone response: an expression of periodic hormonogenesis (1976) J Clin Endocrinol Metab, 43 (4), pp. 913-918eng
hcfmusp.relation.referenceManenschijn, L., Koper, J.W., van den Akker, E.L., A novel tool in the diagnosis and follow-up of (cyclic) Cushing's syndrome: measurement of long-term cortisol in scalp hair (2012) J Clin Endocrinol Metab, 97 (10), pp. E1836-E1843eng
hcfmusp.relation.referenceMinanni, C.A., De Almeida Cardoso, A.L., de Albuquerque Albuquerque, E.V., Fatal factitious Cushing syndrome (Münchhausen's syndrome) in a patient with macroprolactinoma and silent corticotrophinoma: case report and literature review (2015) Clin Diabetes Endocrinol, 4 (1), p. 3eng
hcfmusp.relation.referencePalui, R., Sahoo, J., Kamalanathan, S., Kar, S.S., Selvarajan, S., Durgia, H., Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis (2018) J Endocrinol Invest, 41 (12), pp. 1445-1455eng
hcfmusp.relation.referencePivonello, R., De Martino, M.C., Cappabianca, P., The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery (2009) J Clin Endocrinol Metab, 94 (1), pp. 223-230eng
hcfmusp.relation.referenceCastinetti, F., Guignat, L., Giraud, P., Ketoconazole in Cushing's disease: is it worth a try? (2014) J Clin Endocrinol Metab, 99 (5), pp. 1623-1630eng
dc.description.indexPubMedeng
hcfmusp.citation.scopus1-
hcfmusp.scopus.lastupdate2024-04-12-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/25
LIM/25 - Laboratório de Endocrinologia Celular e Molecular

Artigos e Materiais de Revistas Científicas - LIM/42
LIM/42 - Laboratório de Hormônios e Genética Molecular


Files in This Item:
File Description SizeFormat 
art_MACHADO_Resolution_of_Cyclicity_After_Pasireotide_LAR_in_a_2021.PDF
  Restricted Access
publishedVersion (English)708.29 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.